IR-Center Handelsblatt
Unternehmenssuche:

Hardman & Co Research

News Detail

EQS-News News vom 30.03.2020

Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further

Hardman & Co Research
30-March-2020 / 15:05 GMT/BST

Hardman & Co Research: $52.5m US deal strengthens balance sheet further

Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Alkindi(R) is currently being rolled out through key European markets and has been submitted to the FDA for approval, with a PDUFA date set at 29 September 2020. Meanwhile, Diurnal has signed an exclusive US commercial deal with Eton Pharmaceuticals, a specialty pharma company focused on hospital and paediatric products. This, together with the recent Placing, has strengthened the balance sheet.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/52-5m-us-deal-strengthens-balance-sheet-further/

If you are interested in meeting the company, you can register your interest by clicking on the above link.

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall


+44 20 7194 7632

 

[email protected]
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

show this